Gothenburg, Sweden, June 13, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present an abstract at the IBAGS XIV triennial meeting, held on June 13-16, 2023, in Stockholm, Sweden. The abstract “ISP – a phenotypic and translational approach for drug discovery in basal ganglia-related disorders” will be presented by Daniel Andersson, Director of Biology at IRLAB.

The abstract titled “ISP – a phenotypic and translational approach for drug discovery in basal ganglia-related disorders”, was authored by D.R. Andersson, S. Oleszko, E. Werner, S. Waters, C. Sonesson, P. Svensson, N. Waters at IRLAB. It will be displayed as a poster presentation throughout the duration of the event.

The IBAGS XIV triennial meeting is a major event gathering scientists who investigate the brain’s basal ganglia at all levels (from molecules to behavior) as well as neurological and psychiatric disorders of basal ganglia origin, including Parkinson’s disease, Huntington’s disease, obsessive-compulsive disorders, depression, schizophrenia, and drug addiction. Attending the meeting is around 350-400 researchers and professionals, globally, working with a wide range of advanced research techniques suitable for molecular, cellular, system-level investigations and animal behavior.

More information can be found on the meeting’s webpage at: https://2023.ibags.global/

For more information:

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, is the company’s most advanced program and was licensed to Ipsen in 2021. A second candidate, pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB to present at the scientific conference XIV Triennial Meeting of the International Basal Ganglia Society (IBAGS)